quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·49d
PRRelease
Alnylam Pharmaceuticals Inc. logo
Tenaya Therapeutics Inc. logo

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

ALNY· Alnylam Pharmaceuticals Inc.TNYA· Tenaya Therapeutics Inc.
Health Care
Original source

Companies

  • ALNY
    Alnylam Pharmaceuticals Inc.
    Health Care
  • TNYA
    Tenaya Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 16ALNYUpdateJefferies$330.00
  • Jan 28ALNYUpdateBarclays$527.00
  • Jan 7ALNYUpdateOppenheimer$500.00
  • Aug 4ALNYUpdateWolfe Research-
  • Aug 4ALNYUpdateOppenheimer$490.00
  • Jul 30ALNYUpdateRaymond James$370.00

Related

  • PR3d
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
  • SEC7d
    SEC Form DEFA14A filed by Tenaya Therapeutics Inc.
  • SEC7d
    SEC Form DEF 14A filed by Tenaya Therapeutics Inc.
  • PR7d
    Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
  • INSIDER16d
    SEC Form 4 filed by Mclaughlin Melissa
  • INSIDER16d
    SEC Form 3 filed by new insider Mclaughlin Melissa
  • SEC17d
    SEC Form DEFA14A filed by Alnylam Pharmaceuticals Inc.
  • SEC17d
    SEC Form DEF 14A filed by Alnylam Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022